Repligen (RGN) AI Stock Analysis

Company Guidance

For full year 2026, Repligen guides to $844 million to $852 million of revenue, or $848 million at the midpoint, representing 14.5% to 15.5% reported growth and 12% to 13% organic growth, including approximately $24 million from BioLife, an approximately 1-point headwind from the sale of PolyMem operations, and neutral foreign currency; franchise guidance is filtration flat to slightly down, chromatography greater than 30%, proteins mid-teens, and analytics more than 30% growth. The company expects 110- to 160-basis-points of gross margin expansion, adjusted operating income of $135 to $139 million, adjusted operating margin of 16% to 16.3%, adjusted other income of $18 million, an adjusted tax rate of approximately 22%, adjusted fully diluted earnings per share of $2.05 to $2.09, and CapEx of approximately 3% to 4% of 2026 revenue; fourth quarter organic growth is expected to be in the range of the updated full year outlook, fourth quarter gross margin within the full year guidance, and operating expenses up low-double-digits million sequentially. For 2027, assuming the market is growing high-single-digits and absent a material change in foreign exchange rates, reported top-line growth is positioned at least 25%, revenue is expected to exceed $1 billion, and BioLife is expected to deliver at least $0.05 of Year 1 accretion, while the company continues to target outpacing market growth by more than 500 basis points; the 2027 framework is not a formal guidance.